Atai Life Sciences在其财务战略中选择比特币（BTC）投资

在当前具有挑战性的经济状况中，Atai Life Sciences在其金融战略中选择了比特币投资。

Amid the current challenging economic condition termed as biotech winter, Atai Life Sciences has announced Bitcoin Investment in its financial strategy. The company, known for using psychedelics like DMT and MDMA in mental health treatment, has decided to invest $5 million in Bitcoin.

在目前被称为生物技术冬季的挑战性经济状况中，Atai Life Sciences宣布了比特币投资其金融战略。该公司以在心理健康治疗中使用DMT和MDMA等迷幻药而闻名，已决定向比特币投资500万美元。

Founder and chairman Christian Angermayer explains this decision in a detailed Substack post. He highlights the huge financial demands of drug development, which takes more than a decade to secure regulatory approvals. High inflation and rising interest rates put pressure on companies to adopt robust strategies to sustain daily operations.

创始人兼董事长克里斯蒂安·安吉尔默（Christian Angermayer）在详细的替代帖子中解释了这一决定。他强调了药物开发的巨大财务需求，这需要十多年的时间才能获得监管部门的批准。高通货膨胀和利率上升给公司带来压力，要求公司采取强大的策略来维持日常运营。

Recent data and a TechCrunch report highlight how many biotech startups struggle with securing sufficient funds. Investors and experienced industry analysts observe these emerging trends and fully realize the harsh competitive realities in the biotech domain. Atai Life Sciences is actively exploring unconventional financial options and selecting Bitcoin to counter inflation risks effectively. The company is addressing traditional cash reserve inefficiencies by introducing digital currency solutions for improved performance. This strategic move aims to preserve capital and boost asset value during times of severe financial precarity.

最近的数据和TechCrunch报告强调了有多少生物技术初创公司在获得足够的资金方面努力。投资者和经验丰富的行业分析师观察了这些新兴趋势，并充分意识到了生物技术领域的严峻竞争现实。 Atai Life Sciences正在积极探索非常规财务选择，并选择比特币有效地应对通货膨胀风险。该公司通过引入数字货币解决方案以提高性能来解决传统现金储备效率低下。这一战略举动旨在在严重的财务pre义时期维护资本并提高资产价值。

(Related: Atai Among Biotech Firms Investing In Bitcoin As Startups Face Funding Crisis)

（相关：在生物技术公司投资比特币时，ATAI面临资金危机）

Atai Life Sciences has made a noteworthy move that reflects a broader trend of public medical companies increasingly engaging with Bitcoin. Quantum BioPharma is allocating a total of $3.5 million to cryptocurrencies, beginning with a $1 million investment. Semler Scientific is making a substantial commitment by purchasing 3,192 Bitcoins for $280.4 million to bolster its holdings. The companies are evidently keen on using cryptocurrencies to mitigate financial instability and economic challenges. These investments highlight a strategic shift, encouraging public medical firms to engage with digital currencies more actively.

Atai Life Sciences做出了一个值得注意的举动，这反映了公共医疗公司越来越多地与比特币互动的更广泛趋势。从100万美元的投资开始，量子生物制药总共将350万美元分配给加密货币。 Semler Scientific通过以2.804亿美元的价格购买3,192个比特币来促进其持股，这做出了重大承诺。这些公司显然热衷于使用加密货币来减轻金融不稳定和经济挑战。这些投资强调了战略转变，鼓励公共医疗公司更积极地与数字货币互动。

Firms such as Hoth Therapeutics, Acurx Pharmaceuticals, and Enlivex Therapeutics are each investing $1 million in Bitcoin. These companies are adopting diversified financial strategies to shield them from a worsening economic downturn. They are converting portions of their treasury into Bitcoin to safeguard against inflation and enhance financial returns. Investors recognize these proactive moves as strategies that strengthen financial portfolios during uncertain market conditions. These companies are embracing digital currencies to safeguard their assets and strive for better returns in a volatile market.

Hoth Therapeutics，Acurx Pharmaceuticals和Enlivex Therapeutics等公司都向比特币投资了100万美元。这些公司正在采用多元化的财务战略，以保护他们免受经济不景气的恶化。他们正在将财政部的一部分转换为比特币，以保护通货膨胀并提高财务回报。投资者认为这些积极主动的举动是在不确定的市场条件下加强金融投资组合的策略。这些公司正在采用数字货币来维护其资产，并努力在动荡的市场中获得更好的回报。

Christian Angermayer, the founder and chairman of Atai Life Sciences, has disclosed that the company is investing in Bitcoin to hedge against inflation risks and diversify its short-term assets. Atai’s Bitcoin strategy is designed to counter market volatility and maintain a balanced portfolio. They are arranging portfolios with US dollars, short-term securities, and stocks to minimize market risk. This approach ensures the company’s financial runway through 2027 and supports biotech funding endeavors. The team is adeptly navigating market fluctuations and funding complexities with strategic investments and agile decision-making. Atai is committed to robust financial planning while pursuing innovative investment opportunities every day.

ATAI Life Sciences的创始人兼董事长Christian Angermayer透露，该公司正在投资比特币，以抵制通货膨胀风险并使其短期资产多样化。 Atai的比特币战略旨在抵消市场波动和保持平衡的投资组合。他们正在用美元，短期证券和股票安排投资组合，以最大程度地降低市场风险。这种方法可确保公司在2027年的金融跑道，并支持生物技术资金努力。该团队通过战略投资和敏捷的决策来熟练地导航市场波动和资金复杂性。 Atai致力于强大的财务计划，同时每天寻求创新的投资机会。

Atai Life Sciences saw a modest share price increase after announcing its strategic Bitcoin investment. They keep share prices below the 2021 post-IPO peak as the market responds. Atai ranks as the 52nd largest public company Bitcoin holder by these strategic financial moves.

Atai Life Sciences在宣布其战略性比特币投资后，股价略有上涨。随着市场的回应，他们将股票价格保持在2021年IPO峰的低于2021年。通过这些战略财务转会，Atai是第52大的上市公司比特币持有人。

Investors show cautious optimism as they integrate cryptocurrencies into corporate treasuries across industries. Biopharma companies demand financial stability for long-term research and strict regulatory compliance. This management drives innovative strategies that strengthen investor confidence and support dynamic growth plans.

投资者将加密货币纳入整个行业的公司国库时表现出谨慎的乐观情绪。生物制药公司需要财务稳定性，以进行长期研究和严格的监管合规性。这种管理推动了创新策略，从而增强了投资者的信心并支持动态增长计划。

Atai Life Sciences and other medical firms are now adopting the Bitcoin strategy to handle financial challenges during economic downturns. These companies highlight a fundamental shift in managing finances while enduring prolonged economic stress and uncertainty. Biopharmaceutical firms are continually confronting escalating operational costs and slow regulatory processes. Cryptocurrencies now provide companies with novel ways to manage assets and hedge against fiscal instability. These digital tools empower firms to enhance financial strategies and navigate economic turbulence effectively. Firms are quickly adapting to these solutions as they seek robust financial resilience during market challenges.

ATAI生命科学和其他医疗公司现在正在采用比特币战略来应对经济低迷期间的财务挑战。这些公司重点介绍了管理财务的根本转变，同时忍受了长期的经济压力和不确定性。生物制药公司正在不断面对不断升级的运营成本和缓慢的监管过程。现在，加密货币为公司提供了管理资产和对冲财政不稳定的新方法。这些数字工具授权公司有效地增强财务战略并有效地导航经济动荡。当公司在市场挑战期间寻求强大的财务弹性时，公司正在迅速适应这些解决方案。